title: A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis.
abstract: The optimal dose and timing of 5-HT(3) antagonist administration for prophylaxis against postoperative nausea and vomiting (PONV) remains controversial. Although 5-HT(3) antagonists seem to be most effective when administered near the end of surgery, there are no data on the comparative efficacy or costs associated with the 5-HT(3) antagonists dolasetron and ondansetron when administered at the end of the operation. In this double-blinded study, 200 outpatients undergoing otolaryngologic procedures with a standardized general anesthetic received 4 (O4) or 8 mg (O8) of ondansetron or 12.5 (D12.5) or 25 mg (D25) of dolasetron IV within 30 min before the end of surgery. A blinded observer recorded the emetic episodes, maximum nausea score, recovery room resource and drug use, nursing time spent managing PONV, times to achieve discharge criteria from the Phase 1 and 2 recovery units, postdischarge emesis, and patient satisfaction. Total costs were calculated by using the perspective of a free-standing surgicenter. There were no differences in patient demographics, incidence of PONV, need for rescue medications, time spent in the recovery areas, unanticipated hospital admissions, or patient satisfaction among the four treatment groups. The mean total costs (95% confidence intervals) to prevent PONV in one patient were lowest in the D12.5 group: $23.89 (17.18-28.79) vs $37.81 (30.29-45.32), $33.91 (28.92-39.35), and $75.18 (61.13-89.24) for D25, O4, and O8, respectively. Excluding nursing labor costs did not alter this finding: $18.51 (14.18-22.85), $34.77 (28.03-41.49), $31.77 (28. 92-39.35), and $71.76 (58.17-85.35) for D12.5, D25, O4, and O8, respectively. We conclude that 12.5 mg of dolasetron IV is more cost effective than 4 mg of ondansetron IV for preventing PONV after otolaryngologic surgery and is associated with similar patient satisfaction.
  
  
  CONCLUSIONS
  When administered at the end of surgery, 12.5 mg of dolasetron IV is as effective as 25 mg of dolasetron IV, 4 mg of ondansetron IV, and 8 mg of ondansetron IV in preventing emetic symptoms after otolaryngologic surgery and was associated with similar patient satisfaction at a reduced cost. There were no differences in the antiemetic efficacy of the 4 and 8 mg doses of ondansetron.
authors.affiliation: Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235-9068, USA.
authors.forename: E
authors.initials: E
authors.lastname: Zarate
authors.forename: M F
authors.initials: MF
authors.lastname: Watcha
authors.forename: P F
authors.initials: PF
authors.lastname: White
authors.forename: K W
authors.initials: KW
authors.lastname: Klein
authors.forename: M
authors.initials: M
authors.lastname: Sa Rego
authors.forename: D G
authors.initials: DG
authors.lastname: Stewart
mesh_terms: D000556:Ambulatory Surgical Procedures; D000932:Antiemetics / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D004311:Double-Blind Method; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D017294:Ondansetron / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D020250:Postoperative Nausea and Vomiting / Q000191:economics* / Q000517:prevention & control*; D011807:Quinolizines / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*
chemical_list: D000932:Antiemetics; D007211:Indoles; D011807:Quinolizines; D017294:Ondansetron; C060344:dolasetron